ALKERMES | ALKS - 流动负债

金融业

USD

USD 4.26B

现金及等价物

USD 351.55M

USD 73.25M

USD 1.36B

USD 599.5M

USD 1.58B

股息收益率

0

USD -48.28M

USD 80.26M

1.8K

EPS每股收益

USD -0.4

股本和储备

USD 1.75B

USD 331.33M

债务利息支出

USD 20.89M

USD 8.54M

USD 1.48B

USD 8.55B

USD -66.48M

USD 1.75B

USD -48.28M

普通股股本

USD 166.46M

39.33

USD -61.93M

USD 392.91M

销售和管理费用

USD 264.59M

USD 336.7M

贸易债权人

USD 102.36M

应收帐款人

USD 407.63M

	流动负债	更改		日
AbbVie	USD 42.1B		1.19B	2026-03
Acadia Pharmaceuticals	USD 305.52M		28.41M	2026-03
ALKERMES	USD 599.5M		56.06M	2026-03
Amgen	USD 24.96B		534M	2026-03
Biogen	USD 3B		350.5M	2026-03
BioMarin Pharmaceutical	USD 793.15M		34.12M	2026-03
Bristol-Myers Squibb	USD 19.16B		4.26B	2026-03
Coherus Biosciences	USD 140.39M		231.91M	2025-12
Eli Lilly	USD 36.63B		1.41B	2026-03
Gilead Sciences	USD 9.48B		2.34B	2026-03
Heron Therapeutics	USD 90.52M		5.58M	2026-03
Ionis Pharmaceuticals	USD 717M		66M	2026-03
J&J	USD 57.72B		3.59B	2026-03
Malin Corporation	EUR 1000K		500K	2024-12
Merck	USD 26.94B		1.38B	2026-03
Minerva Neurosciences	USD 2.29M		381K	2025-12
Nektar Therapeutics	USD 53.54M		12.8M	2025-12
Neurocrine Biosciences	USD 831.7M		88.3M	2026-03
Otsuka Holdings	JPY 686.12B		63B	2026-03
Ovoca Bio	EUR 186K		2.26M	2025-06
Pfizer	USD 34.35B		2.64B	2026-03
Regeneron Pharmaceuticals	USD 5.11B		739.3M	2026-03
Vertex Pharmaceuticals	USD 3.88B		19.4M	2026-03